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For a long time, clinical trials have been designed in a fairly standard way. In 1 
particular, in confirmatory randomized clinical trials (RCTs), widely considered the 2 
top of the evidence pyramid, each patient typically has a 1:1 chance of being 3 
allocated to the experimental or the control treatment. Such scheme involves a large 4 
number of patients, due to the often modest expected benefits (“effect size”), while 5 
the statistical  requirements to control misconclusions are quite rigid: the type I 6 
error rate of false positive findings is consensually fixed at 5% and that of type II 7 
error rate of false negative findings fixed at most at 20%. Indeed, the effect size is 8 
the factor of greatest impact on both sample size and power computations, which 9 
explain the failure of most RCTs in critical care medicine to demonstrate the desired 10 
effect size (10.1% on average), often largely above the observed one (1.4% on 11 
average, [1]). 12 
If RCT must be characterized ethically by the principle of equipoise, that is, of some 13 
genuine uncertainty over whether a treatment will be beneficial, then it has been 14 
argued that such negative and likely underpowered trials are unethical [1]: 15 
participants may be called to sacrifice their own best interests for the benefit of 16 
future patients. Lastly, RCTs are also faced with feasibility issues, when dealing with 17 
interventions that could not be easily controlled and quantified such as ICU 18 
admission and mechanical ventilatory support. 19 
For all these reasons, it has been claimed that effectiveness of clinical trials should 20 
be improved by adopting a more integrated model that increases flexibility and 21 
maximizes the use of accumulated knowledge. Novel tools include the smart use of 22 
supplementary evidence, adaptive designs, and Bayesian designs. 23 
Using supplementary evidence for precision medicine 24 
First, merging the strength of randomized clinical trials on homogeneous 25 
populations (carefully selected through inclusion/exclusion criteria) and 26 
observational studies could be promising.  In this regard, mixed randomized trials 27 
that allocate patients first to trial arm and then to treatment group have been 28 
proposed [2]. This solution seems to be mostly applicable to population-based 29 
screening or interventions that appear far from the ICU setting. 30 
In the ICU, the complexity of critical illness syndromes is a fundamental justification 31 
for the adoption of a personalized approach to research [3]. Thus, identifying more 32 
effectively the patients who will benefit from treatment, by refining critical illness 33 
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(pheno)types of patients, has been the motivation for innovative proposals of the 1 
so-called “precision medicine”. The change of paradigm has been mostly beneficial 2 
in the oncology setting, where widespread changes in clinical practice for diagnosis 3 
and treatment have been increasingly based on genomic features [4].  4 
To increase our knowledge on the population that should be targeted when 5 
designing a particular trial, Bioinformatics and Machine Learning have provided 6 
useful tools for the exploration of the huge amount of data derived from new 7 
genomic platforms, physiologic waveforms, RCTs and electronic medical records. 8 
This was exemplified since the early 2000s with the development of the MIMIC II 9 
(Multiparameter Intelligent Monitoring in Intensive Care) databases that contain 10 
physiologic signals and vital signs time series captured from ICU patients [5]. To 11 
take full advantage of these big data, prediction models should be validated 12 
rigorously given their potential to influence decision making [6]. 13 
In the light of what has been done in oncology, providing precise information about 14 
ICU phenotypes should lead to targeted treatments or interventions in pre-specified 15 
subpopulations. Pivotal clinical trials of such therapies will then naturally be based 16 
on innovative adaptive and/or Bayesian designs. 17 
Adaptive designs 18 
Adaptive designs can make clinical trials more flexible by utilising results 19 
accumulating in the trial to modify the trial course in accordance with pre-specified 20 
rules, aiming at improving the study power and reducing sample size and trial cost. 21 
First proposed in oncology to assess many treatments and biomarkers, they have 22 
raised many controversial discussions from the beginning [7], and are still 23 
underused [8] and surrounded by misconceptions [9]. Nevertheless, they appear to 24 
provide a possible blueprint for therapeutic development in the ICU. 25 
Many innovative adaptive designs have been proposed, including enrichment 26 
designs, marker-stratified designs, and marker strategy designs (umbrella trials, 27 
basket trials) (Table). Most of these designs aim at treating more patients with more 28 
effective treatments, or identifying efficacious drugs for specific subgroups of 29 
patients. Such “enrichment” adaptive designs give investigators the ability to study 30 
treatment approaches in multiple patient phenotypes within a single trial, while 31 
maintaining a reasonable overall sample size, based on their biomarker profiles 32 
including omics [10], and shortening the time for drug development. Conversely, 33 
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treatments found to be ineffective can be dropped from a study for selected patient 1 
subpopulations. 2 
Bayesian designs 3 
Bayesian statistics and adaptive designs go often hand in hand. For instance, taking 4 
multiple looks at the data is (statistically) not a problem, since in a Bayesian 5 
framework such operation does not have to be adjusted for in any special way. 6 
Thus, many adaptive designs have been proposed in this framework. They include 7 
Bayesian adaptive biomarker/enrichment designs or randomization-adaptive 8 
designs that update random allocation probabilities, so that more patients are 9 
allocated to the most promising strategy as evidence accumulate [11]. 10 
Bayesian designs can compare multiple active treatment strategies in real-world 11 
settings by allowing for the evaluation of more than one new agent at the same time 12 
and by dropping/adding arms when a sufficient level of evidence is reached [12]. 13 
Such a Multi-Arm Multi-Stage (MAMS) design has been proposed in sepsis-like 14 
patients [13]. 15 
Conclusions   16 
Adaptive and Bayesian designs are a methodologically sound way to improve clinical 17 
trials in critical care but they add significant complexity [14]. First, outcomes should 18 
be available soon enough to permit adaptation of the trial design. Furthermore, 19 
design is impacted by the accumulated data. This requires statisticians to be 20 
engaged both in the planning phase and in the conduct phase of the trial, which 21 
may delay its large use in ICU as observed in other settings [15]. However, 22 
multidisciplinary collaborations and team science including experts from Genetics, 23 
Bioinformatics and Statistics appear a key to the success of these new design 24 
strategies in ICU. 25 
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Table: Schematization of proposed biomarker-based adaptive designs  1 
 2 
 Enrichment or targeted designs 
Denomination Basket trial Umbrella 
trial 
Platform trials Biomarker-
based 
Bayesian 
adaptive trial 
Main setting Single 
treatment, 
single 
biomarker, 
different 
subsets of 
patients 
One subset 
of patients, 
different 
biomarkers, 
Different 
drugs  
Multiple 
biomarkers 
and multiple 
drugs 
 
Response-
adaptive 
randomization  
Enrollment All the 
subsets are 
enrolled  
One drug for 
one 
biomarker 
 
(separate 
enrichment 
design for 
each 
biomarker) 
Randomization 
between strata 
(allocation 
probabilities 
modified to 
favor 
assignment of 
drugs with 
higher within-
stratum 
response rate)   
Modified 
allocation 
probabilities 
within each of 
biomarker-
based 
treatment 
Advantages Access to 
targeted 
agents for 
patients in 
various 
subsets 
 
Conclusions 
specific to 
the patient 
subset 
 
More patients 
allocated to 
the best 
treatment 
Incorporate 
external 
information, 
and report 
based on 
probabilities 
on effect size  
Drawbacks Rely on the 
assumption 
that profiling 
based on 
biomarker is 
enough 
Feasibility, 
notably for 
rare diseases 
(poor accrual 
and slow trial 
progress) 
Increased 
samples and 
heterogeneity 
Larger 
complexity 
and the 
involvement 
of statisticians 
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